Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease. As announced on October 4th, 2023, under the terms of the agreemen.

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Limited pipeline catalysts until 2025 mean a "show me" story status. Higher R&D costs and uncertainty for the future. A new spin-off in the consumer division with no 2025 profitability targets. Sanofi is still attractive, but we are lowering our target price.

Sanofi: A Shift In The Story

Regeneron Pharmaceuticals

Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales

Sanofi plans to file for U.S. approval of wider use of its anti-inflammatory drug Dupixent against "smoker's lung", also known as COPD, after a second large trial showed significant benefits.

Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win

Dupixent ® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

AstraZeneca

The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.

CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage

The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.

CDC releases 77,000 additional doses of Sanofi-AstraZeneca's RSV drug

Amgen

Gilead Sciences

Merck

Pfizer

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and likely 2024.

5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now

French prosecutors have opened a preliminary investigation into multinational pharmaceutical company Sanofi over possible market manipulation.

French prosecutors investigating Sanofi over possible market manipulation

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results.

Pfizer and Sanofi shares fall, which one to scoop up?

Sanofi's third-quarter results weren't great, and the company announced a business separation. The biotech will lower its operating income margin target for 2025, which scared off many investors.

This Stock Just Dropped By 15%: Is It a Buy?

CAMBRIDGE, Mass. , Nov. 2, 2023 /PRNewswire/ -- Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's ambition to provide equitable access to healthcare using innovative solutions for hard-to-solve health disparities.

Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities

Ligand Pharmaceuticals

SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million.

Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million

Nationwide storytelling movement to showcase diverse voices of the type 1 diabetes community, including internationally recognized stars Usher, Robin Arzón, and Adam Schefter, to share experiences and encourage people to get screened The 1 Pledge movement commences with surround-sound event in New York City's Times Square; continues throughout the year with events and social storytelling Screening for type 1 diabetes can detect the disease before noticeable symptoms arise1; people can pledge to get themselves and their family screened at The1Pledge.com BRIDGEWATER, N.J. , Nov. 1, 2023 /PRNewswire/ -- Sanofi, a leader in diabetes care, today launched "The 1 Pledge" movement, a nationwide education campaign urging families to get screened for type 1 diabetes so that those who will eventually be affected by the disease can begin to prepare as soon as possible.

Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.

AbbVie

Bristol-Myers

Johnson & Johnson

Eli Lilly

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.

Investor patience tested as pharmaceutical stocks take a tumble

MeiraGTx Holdings plc

MeiraGTx Holdings PLC (NASDAQ:MGTX) shares gained more than 25% after it announced Sanofi SA (ADR) (NYSE:SNY), a pharma giant best known for its vaccines, is purchasing 4 million of the gene company's shares at a price of $7.50 per share for a total $30 million investment. MeiraGTx stock was up 25.4% at US$4.64 late morning on Monday, while Sanofi shares gained 3.5% at US$44.63.

MeiraGTx shares take off on $30M investment by Sanofi

Chevron

Microsoft

Advanced Micro Devices

Comcast

Cisco Systems

Datadog

L3Harris

Southwest Airlines

Newell Brands

ON Semiconductor

Valley National

Vertex Pharmaceuticals

Western Digital

Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook:

Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest

Shares of MeiraGTx Holdings PLC MGTX, -4.88% jumped 14% premarket on Monday after the gene therapy company announced that French drugmaker Sanofi SNY, -19.13% has made a $30 million investment.

MeiraGTx shares jump as Sanofi invests in gene therapy

Sanofi (NASDAQ:SNY ) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Eva Schaefer-Jansen - Head of Investor Relations Paul Hudson - Chief Executive Officer Jean-Baptiste de Chatillon - Executive Vice President, Chief Financial Officer Houman Ashrafian - Global Head of R&D Julie Van Ongevalle - Executive Vice President, Consumer Healthcare Brian Ford - Head Specialty Care, North America and US Country Lead Thomas Triomphe - Executive Vice President, Vaccines Olivier Charmeil - Executive Vice President, General Medicines Conference Call Participants Luisa Hector - Berenberg Emily Field - Barclays Peter Welford - Jefferies Graham Parry - BofA Timothy Anderson - Wolfe Peter Verdult - Citi David Risinger - Leerink Florent Cespedes - Societe Generale Simon Baker - Redburn Seamus Fernandez - Guggenheim Richard Vosser - JPMorgan Eva Schaefer-Jansen [starts abruptly] You have joined the meeting as an attendee and will be muted throughout the meeting. This meeting is being recorded.

Sanofi (SNY) Q3 2023 Earnings Call Transcript

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.

Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit

Sanofi (NYSE: SNY ) stock fell about 15% overnight after it predicted slower profit growth next year. The French drug company also said it will follow rivals and spinoff its consumer health business.

SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff

Sanofi stock crashed Friday after the company reported light third-quarter earnings and sales, and unveiled a looming spinoff.

Sanofi Crashes 16% As Third Quarter Comes In Light Ahead Of Spinoff

Shares of French drugmaker Sanofi fell as much as 16% on Friday after after hiking its research-and-development expense guidance as well as its expectations for taxes.

Sanofi shares skid as French drugmaker outlines higher R&D expenses, taxes

Amazon

Intel

NatWest Group plc 

Intel Corp. stock INTC, -0.94% jumped 8% after the chipmaker beat expectations for its third quarter and delivered an upbeat forecast for the current quarter.

Shares of Amazon, Intel climb after earnings beats, as NatWest and Sanofi tumble on warnings, and other stocks on the move

Sanofi on Friday mapped out a potential separate listing of its consumer healthcare business from the fourth quarter of next year, as it plans to shore up new drug development spending at its core business.

News for Sanofi Stock (SNY)